No Data
Beijing Leadman Biochemistry (300289.SZ) has been re-certified as a high-tech enterprise.
Gelonghui reported on February 11 that Beijing Leadman Biochemistry (300289.SZ) announced that it recently received the "High-tech Enterprise Certificate" jointly issued by the Peking Municipal Science and Technology Commission, the Peking Municipal Finance Bureau, and the State Taxation Administration's Peking Taxation Bureau. The company has once again passed the qualification for high-tech enterprises, with the certificate number GS202411000092, issued on December 19, 2024, and is valid for three years.
Leadman: 2024 performance forecast
Beijing Leadman Biochemistry (300289.SZ): Currently, there are no registered certificates for products related to Monkeypox Virus Testing.
On January 15, Gelonghui reported that Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the company currently has not applied for any registration certificates for products related to Monkeypox Virus Testing. As for the specific review timeline of patents related to Monkeypox Virus Testing, please refer to the information released by the relevant departments, and the company will continue to closely monitor related developments.
Beijing Leadman Biochemistry (300289.SZ): Hepatitis B and C test kits can be used to detect the corresponding viruses.
Gelonghui on January 8 reported that Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the company's testing kits for hepatitis B and hepatitis C can be used to detect the corresponding viruses.
Beijing Leadman Biochemistry (300289.SZ): Medical AI transformation is currently one of the industry development trends closely watched by the company.
Gelonghui November 8th | Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the medical AI transformation is currently one of the closely watched industry development trends by the company.
Beijing Leadman Biochemistry (300289.SZ): The patented application scenarios of microfluidic fluorescence immunoassay chip technology are in the field of clinical immunological analysis.
Gelonghui November 1st | Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the patented application scenarios of the microfluidic fluorescence immunoassay chip technology obtained by the company are in the field of immunological analysis in clinical testing.